Acemannan ameliorates STZ-activated diabetes by attenuating high glucose via inhibiting inflammatory cytokines and apoptosis pathway

Asma B. Omer; Hisham N. Altayb; Fahad A. Al-Abbasi; Gaurav Gupta; Mohammed Muqtader Ahmed; Amira M. Alghamdi; Sami I. Alzarea; Nadeem Sayyed; Muhammad Shahid Nadeem; Imran Kazmi

doi:10.1016/j.ijbiomac.2023.127127

Acemannan ameliorates STZ-activated diabetes by attenuating high glucose via inhibiting inflammatory cytokines and apoptosis pathway

Asma B. Omer
, Hisham N. Altayb
, Fahad A. Al-Abbasi
, Gaurav Gupta
, Mohammed Muqtader Ahmed
, Amira M. Alghamdi
, Sami I. Alzarea
, Nadeem Sayyed
, Muhammad Shahid Nadeem
, Imran Kazmi

Pharmaceutics

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Acemannan, the main polysaccharide in Aloe vera, is a -(1, 4)-acetylated polymannose. According to numerous research findings, acemannan is a viable alternative for the treatment of pathological disorders. Streptozotocin (STZ, 60 mg/kg) administered intraperitoneally caused type 2 diabetes in rats. The current study sought to determine the anti-diabetic efficacy of acemannan (25 and 50 mg/kg) in STZ-injected rats. Different biochemical parameters including HbA1C, glucose and serum insulin, lipid profile, inflammatory markers, antioxidant, oxidative balance, liver function test, glycogen and creatinine, and caspase-3 were evaluated. In addition, a molecular docking study was performed to estimate acemannan's binding affinity to inflammatory markers. Acemannan may be a potent anti-diabetic agent for the treatment of diabetic patients, which will aid in future research into alternative diabetes medications.

Original language	English
Article number	127127
Journal	International Journal of Biological Macromolecules
Volume	253
DOIs	https://doi.org/10.1016/j.ijbiomac.2023.127127
State	Published - 31 Dec 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Acemannan
Apoptosis
Docking study
Polysaccharide
Streptozotocin

Access to Document

10.1016/j.ijbiomac.2023.127127

Cite this

Omer, A. B., Altayb, H. N., Al-Abbasi, F. A., Gupta, G., Ahmed, M. M., Alghamdi, A. M., Alzarea, S. I., Sayyed, N., Nadeem, M. S., & Kazmi, I. (2023). Acemannan ameliorates STZ-activated diabetes by attenuating high glucose via inhibiting inflammatory cytokines and apoptosis pathway. International Journal of Biological Macromolecules, 253, Article 127127. https://doi.org/10.1016/j.ijbiomac.2023.127127

@article{843166e7bbdf43cab65c5a8db38e9ade,

title = "Acemannan ameliorates STZ-activated diabetes by attenuating high glucose via inhibiting inflammatory cytokines and apoptosis pathway",

abstract = "Acemannan, the main polysaccharide in Aloe vera, is a -(1, 4)-acetylated polymannose. According to numerous research findings, acemannan is a viable alternative for the treatment of pathological disorders. Streptozotocin (STZ, 60 mg/kg) administered intraperitoneally caused type 2 diabetes in rats. The current study sought to determine the anti-diabetic efficacy of acemannan (25 and 50 mg/kg) in STZ-injected rats. Different biochemical parameters including HbA1C, glucose and serum insulin, lipid profile, inflammatory markers, antioxidant, oxidative balance, liver function test, glycogen and creatinine, and caspase-3 were evaluated. In addition, a molecular docking study was performed to estimate acemannan's binding affinity to inflammatory markers. Acemannan may be a potent anti-diabetic agent for the treatment of diabetic patients, which will aid in future research into alternative diabetes medications.",

keywords = "Acemannan, Apoptosis, Docking study, Polysaccharide, Streptozotocin",

author = "Omer, \{Asma B.\} and Altayb, \{Hisham N.\} and Al-Abbasi, \{Fahad A.\} and Gaurav Gupta and Ahmed, \{Mohammed Muqtader\} and Alghamdi, \{Amira M.\} and Alzarea, \{Sami I.\} and Nadeem Sayyed and Nadeem, \{Muhammad Shahid\} and Imran Kazmi",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = dec,

day = "31",

doi = "10.1016/j.ijbiomac.2023.127127",

language = "English",

volume = "253",

journal = "International Journal of Biological Macromolecules",

issn = "0141-8130",

publisher = "Elsevier B.V.",

}

Omer, AB, Altayb, HN, Al-Abbasi, FA, Gupta, G, Ahmed, MM, Alghamdi, AM, Alzarea, SI, Sayyed, N, Nadeem, MS & Kazmi, I 2023, 'Acemannan ameliorates STZ-activated diabetes by attenuating high glucose via inhibiting inflammatory cytokines and apoptosis pathway', International Journal of Biological Macromolecules, vol. 253, 127127. https://doi.org/10.1016/j.ijbiomac.2023.127127

TY - JOUR

T1 - Acemannan ameliorates STZ-activated diabetes by attenuating high glucose via inhibiting inflammatory cytokines and apoptosis pathway

AU - Omer, Asma B.

AU - Altayb, Hisham N.

AU - Al-Abbasi, Fahad A.

AU - Gupta, Gaurav

AU - Ahmed, Mohammed Muqtader

AU - Alghamdi, Amira M.

AU - Alzarea, Sami I.

AU - Sayyed, Nadeem

AU - Nadeem, Muhammad Shahid

AU - Kazmi, Imran

PY - 2023/12/31

Y1 - 2023/12/31

N2 - Acemannan, the main polysaccharide in Aloe vera, is a -(1, 4)-acetylated polymannose. According to numerous research findings, acemannan is a viable alternative for the treatment of pathological disorders. Streptozotocin (STZ, 60 mg/kg) administered intraperitoneally caused type 2 diabetes in rats. The current study sought to determine the anti-diabetic efficacy of acemannan (25 and 50 mg/kg) in STZ-injected rats. Different biochemical parameters including HbA1C, glucose and serum insulin, lipid profile, inflammatory markers, antioxidant, oxidative balance, liver function test, glycogen and creatinine, and caspase-3 were evaluated. In addition, a molecular docking study was performed to estimate acemannan's binding affinity to inflammatory markers. Acemannan may be a potent anti-diabetic agent for the treatment of diabetic patients, which will aid in future research into alternative diabetes medications.

AB - Acemannan, the main polysaccharide in Aloe vera, is a -(1, 4)-acetylated polymannose. According to numerous research findings, acemannan is a viable alternative for the treatment of pathological disorders. Streptozotocin (STZ, 60 mg/kg) administered intraperitoneally caused type 2 diabetes in rats. The current study sought to determine the anti-diabetic efficacy of acemannan (25 and 50 mg/kg) in STZ-injected rats. Different biochemical parameters including HbA1C, glucose and serum insulin, lipid profile, inflammatory markers, antioxidant, oxidative balance, liver function test, glycogen and creatinine, and caspase-3 were evaluated. In addition, a molecular docking study was performed to estimate acemannan's binding affinity to inflammatory markers. Acemannan may be a potent anti-diabetic agent for the treatment of diabetic patients, which will aid in future research into alternative diabetes medications.

KW - Acemannan

KW - Apoptosis

KW - Docking study

KW - Polysaccharide

KW - Streptozotocin

UR - https://www.scopus.com/pages/publications/85173170165

U2 - 10.1016/j.ijbiomac.2023.127127

DO - 10.1016/j.ijbiomac.2023.127127

M3 - Article

C2 - 37776926

AN - SCOPUS:85173170165

SN - 0141-8130

VL - 253

JO - International Journal of Biological Macromolecules

JF - International Journal of Biological Macromolecules

M1 - 127127

ER -

Acemannan ameliorates STZ-activated diabetes by attenuating high glucose via inhibiting inflammatory cytokines and apoptosis pathway

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this